SecBot SecBot
PRESS-RELEASE ·Filed Jun 4, 2026

AXSM

Axsome Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a routine medical conference update with no material new data or regulatory catalyst. Monitor for any subsequent peer-reviewed publications or label expansion announcements, but no immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$231.48
T+0 close · Jun 4, 2026 · via day close
Latest settled
−14.02%
T+60 · $199.02
Vs SPY
−15.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $231.48entry
  2. T+1 · 6mo ago +0.36%α +2.96% · $232.32
  3. T+5 · 5mo ago +9.63%α +12.18% · $253.77
  4. T+20 · 4mo ago +5.54%α +6.92% · $244.31
  5. T+60 · 3mo ago −14.02%α −15.90% · $199.02

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific Meeting, including post-hoc efficacy analyses and a network meta-analysis comparing SYMBRAVO to gepants for acute migraine treatment. This is a routine scientific conference update with no new regulatory or financial catalysts.

Key Facts

  • Presentations at AHS 68th Annual Scientific Meeting, June 4-7 in Orlando, FL
  • Four SYMBRAVO data presentations: post-hoc composite efficacy, network meta-analysis vs. gepants, sustained pain relief analysis, and safety endpoint analysis
  • No new clinical trial results, regulatory decisions, or financial guidance provided
  • SYMBRAVO is already FDA-approved for acute treatment of migraine

Financial Impact

No financial figures disclosed; routine scientific conference update

Risk Factors

  • No new efficacy or safety signals disclosed that could change competitive positioning
  • Network meta-analysis vs. gepants may not be considered definitive by prescribers

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3306621

Track record

26 reports on AXSM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026